| Revista: | The brazilian journal of infectious diseases |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000290949 |
| ISSN: | 1413-8670 |
| Autores: | Tupinambás, Unaí1 Graco, Dirceu2 Aleixo, Agdemir3 |
| Instituciones: | 1Secretaria de Saude da Belo Horizonte, Belo Horizonte, Minas Gerais. Brasil 2Universidade Federal de Minas Gerais, Faculdade de Medicina, Belo Horizonte, Minas Gerais. Brasil 3Secretaria de Estado da Saude de Minas Gerais, Belo Horizonte, Minas Gerais. Brasil |
| Año: | 2005 |
| Periodo: | Ago |
| Volumen: | 9 |
| Número: | 4 |
| Paginación: | 324-329 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental |
| Resumen en inglés | Combined antiretroviral therapy results in sustained viral suppression and a decrease in mortality and morbidity due to HIV infection. Intrinsic strength, durability and absence of cross-resistance are key factors in the selection of antiretrovirals. Failure with nelfinavir has been associated with two protease gene mutations, D30N and L90M. The D30N mutation does not result in cross-resistance with other protease inhibitors, and it decreases viral fitness. In order to check for this mutation after failure with nelfinavir, the 246 HIV-1 genotyping test was performed on virus samples from 55 patients with failure of nelfinavir as the first protease inhibitor. Most (84%) of the viral strains were of subtype B. Nucleosides associated with mutations (NAM) were observed in 80% of the tests; no INS69, complex 151, K65R and L74V mutations, which give multi-resistance to nucleoside analogue reverse transcriptase inhibitors to tenofovir and DDI, respectively, were observed. In the tests for protease gene mutations, the D30N mutation was found in 57%, L90M in 18% and the wild-type virus in 25%. These data are similar to published reports, showing that alternative therapies used after failure with nelfinavir may be more successful, as the D30N mutation does not cause cross-resistance to other protease inhibitors |
| Disciplinas: | Medicina, Química |
| Palabras clave: | Terapéutica y rehabilitación, Bioquímica, Genética, Antirretrovirales, Nelfinavir, Genotipos, VIH-1, Inhibidores de la proteasa |
| Keyword: | Medicine, Chemistry, Therapeutics and rehabilitation, Biochemistry, Antiretrovirals, Nelfinavir, Genotypes, HIV-1, Protease inhibitors, Genetics |
| Texto completo: | Texto completo (Ver HTML) |
